Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1

Conditions

Neoplasms 2Solid Tumor 1Neoplasm Metastasis 1

Interventions

Paclitaxel 337pembrolizumab 333Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 240Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 170Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 119Prednisone 118Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Doxorubicin 98Leucovorin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 78Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × LY3022855 × Clear all
NCT02265536 2024-10-28

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Eli Lilly and Company

Phase 1 Completed
34 enrolled 17 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01346358 2024-09-19

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
52 enrolled 23 charts
Tumor-Agnostic

Neoplasms

NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
72 enrolled 23 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡